Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 11:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 75 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hypertension, Systolic Clear all
Terminated Phase 2 Interventional Results available

Hemodynamic and Echocardiographic Assessment of Riociguat Effects on Myocardial Wall Contractility and Relaxation Kinetics

NCT01065051
View directory record Official record
Conditions
Hypertension, Pulmonary, Ventricular Dysfunction, Left
Interventions
Riociguat (Adempas, BAY63-2521), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 5, 2026, 11:23 AM EDT
Terminated Phase 3 Interventional Results available

Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension

NCT00170950
View directory record Official record
Conditions
Hypertension
Interventions
Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1, Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2, Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter, Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1, Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2, Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter
Drug
Lead sponsor
Novartis
Industry
Eligibility
55 Years and older
Enrollment
11,506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Oct 5, 2026, 11:23 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Study 2: Effect of Minocycline Treatment on Drug-Resistant Hypertensive Patients

NCT02133885
View directory record Official record
Conditions
Hypertension
Interventions
Minocycline Group, Placebo Group
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Oct 5, 2026, 11:23 AM EDT
Terminated Not applicable Interventional

A Pivotal Study To Evaluate The Effectiveness of Isometric Handgrip Therapy In Prehypertensive And Hypertensive Patients

NCT04467879
View directory record Official record
Conditions
Hypertension, Systolic
Interventions
Zona Plus Device, Control Device
Device
Lead sponsor
Zona Health, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
St Louis, Missouri • Charlotte, North Carolina • Goldsboro, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Oct 5, 2026, 11:23 AM EDT
Completed Phase 3 Interventional

DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension

NCT00330369
View directory record Official record
Conditions
Hypertension
Interventions
Darusentan, Darusentan Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
35 Years to 80 Years
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
67
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Oct 5, 2026, 11:23 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults

NCT03821623
View directory record Official record
Conditions
Hypertension, Aging
Interventions
Nicotinamide riboside, Placebo
Drug · Other
Lead sponsor
Douglas Seals
Other
Eligibility
50 Years and older
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 5, 2026, 11:23 AM EDT
Completed Not applicable Interventional

"Reversibility of Cardiovascular Injury With CPAP Use: Mechanisms Involved"

NCT01317329
View directory record Official record
Conditions
Sleep Apnea, Obstructive, Hypoxia, Hypercapnia, Sleep Disorders, Obesity, Hypertension, Coronary Artery Vasospasm, Right Ventricular Overload, Left Ventricular Function Systolic Dysfunction, Ventricular Hypertrophy
Interventions
Clinically prescribed CPAP therapy
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
21 Years to 50 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 6, 2020 · Synced Oct 5, 2026, 11:23 AM EDT
Recruiting Not applicable Interventional

Polygenic Risk Score Implementation and Stratification for Managing Blood Pressure

NCT06962488
View directory record Official record
Conditions
Hypertension, Atherosclerotic Cardiovascular Disease
Interventions
Regular Care, SBP PRS Dissemination
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 55 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Oct 5, 2026, 11:23 AM EDT
Completed Phase 3 Interventional

Safety/Efficacy of Combo Therapy With Aliskiren & Hydrochlorothiazide vs Therapy With Hydrochlorothiazide Alone in Patients With Hypertension

NCT00387517
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren/HCTZ
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
726 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Oct 5, 2026, 11:23 AM EDT
Withdrawn No phase listed Observational

The Role of Echocardiographic Contrast (Optison) in Enhancing Tricuspid Regurgitation Spectral Doppler Signals

NCT02560116
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Oct 5, 2026, 11:23 AM EDT
Completed Phase 3 Interventional

A Safety and Efficacy Trial of the Combination of Aliskiren / Hydrochlorothiazide (HCTZ)(300/12.5 mg and 300/25 mg) Compared to Aliskiren 300 mg in Hypertensive Patients

NCT00386139
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren/HCTZ
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
881 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Oct 5, 2026, 11:23 AM EDT
Completed Phase 4 Interventional Results available

Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension

NCT00942994
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren/Amlodipine, Aliskiren/Amlodipine and Hydrochlorothiazide (HCTZ)
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
5
States / cities
Little Rock, Arkansas • South Miami, Florida • Mattapan, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 5, 2026, 11:23 AM EDT
Completed Not applicable Interventional Results available

Veteran Peer Coaches Optimizing and Advancing Cardiac Health

NCT02697422
View directory record Official record
Conditions
Cardiovascular Disease (CVD), Hypertension, Hyperlipemia, Obesity
Interventions
Community-based peer health coach intervention
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Up to 75 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 5, 2026, 11:23 AM EDT
Not listed Not applicable Interventional

Clinical Trial to Assess the Effects of Low-fat Dairy on Systolic Blood Pressure

NCT01463085
View directory record Official record
Conditions
Hypertension
Interventions
Low-fat dairy
Other
Lead sponsor
Dairy Research Institute
Other
Eligibility
20 Years to 69 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Glen Ellyn, Illinois
Source: ClinicalTrials.gov public record
Updated May 24, 2012 · Synced Oct 5, 2026, 11:23 AM EDT
Recruiting Not applicable Interventional

BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT

NCT06059638
View directory record Official record
Conditions
Hypertension, Hypertension, Systolic, Hypertension, Essential
Interventions
Medtronic Astra/Azure DR MRI IPG with AVIM therapy Activated, Medtronic Astra/Azure DR MRI IPG with AVIM therapy Deactivated
Device
Lead sponsor
Orchestra BioMed, Inc
Industry
Eligibility
18 Years and older
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
72
States / cities
Scottsdale, Arizona • Glendale, California • Newport Beach, California + 60 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 5, 2026, 11:23 AM EDT
Recruiting Phase 2 Interventional

A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension

NCT07142356
View directory record Official record
Conditions
Uncontrolled Hypertension
Interventions
RTN-001, Matching placebo control
Drug
Lead sponsor
Retension Pharmaceuticals. Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
34
States / cities
Alexander City, Alabama • Birmingham, Alabama • Tucson, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 5, 2026, 11:23 AM EDT
Terminated Phase 3 Interventional

DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension

NCT00353574
View directory record Official record
Conditions
Hypertension
Interventions
Darusentan
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
35 Years to 80 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
53
States / cities
Mobile, Alabama • Tucson, Arizona • Inglewood, California + 48 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Oct 5, 2026, 11:23 AM EDT
Completed Not applicable Interventional Results available

Effects of the Dietary Approaches to Stop Hypertension(DASH) Sodium-restricted Diet in Diastolic Heart Failure

NCT00939640
View directory record Official record
Conditions
Diastolic Heart Failure, Hypertensive Heart Disease
Interventions
DASH/sodium-restricted diet (SRD)
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
50 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 5, 2026, 11:23 AM EDT
Terminated Not applicable Interventional

A Multicenter Study to Evaluate the ROX Coupler in Subjects With Hypertension

NCT02895386
View directory record Official record
Conditions
Hypertension, High Blood Pressure
Interventions
ROX Coupler, Sham procedure
Device · Other
Lead sponsor
ROX Medical, Inc.
Industry
Eligibility
22 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
13
States / cities
Birmingham, Alabama • Gainesville, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated May 13, 2019 · Synced Oct 5, 2026, 11:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Smartphone App-guided Inspiratory Muscle Strength Training for Lowering Systolic Blood Pressure

NCT06229873
View directory record Official record
Conditions
Blood Pressure, Vascular Function, Adherence, Treatment
Interventions
App-Based Inspiratory Muscle Strength Training, Clinic-Based Inspiratory Muscle Strength Training
Device
Lead sponsor
University of Colorado, Boulder
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 5, 2026, 11:23 AM EDT
Completed No phase listed Observational

Systolic Pressure Intervention Trial Factors Affecting Factors Affecting Atherosclerosis Study

NCT01475747
View directory record Official record
Conditions
Hypertension, Chronic Kidney Disease
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
50 Years and older
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
12
States / cities
Palo Alto, California • Denver, Colorado • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2019 · Synced Oct 5, 2026, 11:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pre-clinical Cardiac Dysfunction Among Asymptomatic Hypertensive Patients

NCT00689819
View directory record Official record
Conditions
Hypertension, High Blood Pressure, Ventricular Hypertrophy, Diastolic Dysfunction, Systolic Dysfunction
Interventions
Exercise, Weight Loss, Low Sodium Diet, Smoking Cessation, Pharmaceutical Therapy (no specific therapy; approach guided by the JNC 7 protocol guidelines)
Behavioral · Drug
Lead sponsor
Wayne State University
Other
Eligibility
35 Years to 75 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced Oct 5, 2026, 11:23 AM EDT
Completed Not applicable Interventional Results available

Trial to Address Food Insecurity in Patients With Hypertension (SMART-FI)

NCT05800145
View directory record Official record
Conditions
Hypertension
Interventions
Resource information Supplemental Nutrition Assistance Program (SNAP), community health worker (CHW), medically tailored meals
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 5, 2026, 11:23 AM EDT
Completed Not applicable Interventional Results available

Renal Stent Placement for the Treatment of Renal Artery Stenosis in Patients With Resistant Hypertension

NCT01673373
View directory record Official record
Conditions
Renal Artery Stenosis, Hypertension, Renovascular
Interventions
iCAST™ Rx Stent System
Device
Lead sponsor
Atrium Medical Corporation
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
12
States / cities
Fremont, California • Loveland, Colorado • Clearwater, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2020 · Synced Oct 5, 2026, 11:23 AM EDT